1
|
Basquiera AL, García MJ, Martinez Rolón J, Olmedo J, Laviano J, Burgos R, Caeiro G, Remaggi G, Raña P, Paoletti M, González CM, Fernández I, Pavlovsky A, Perusini MA, Rodriguez A, Guanchiale L, Carvani A, Mandrile L, Figueroa F, Vicente Reparaz A, Fragapane Mathus PN, Garate G, Fauque ME, Kantor G, Cruset S, Gonzalez Lorch JS, Szelagowski M, Giarini MP, Oliveira N, García MC, Ventriglia MV, Pereyra PH, Gutierrez DR, Kusminsky G, Troccoli J, Freitas MJ, Cranco S, Del V Sanchez N, Rey I, Funes ME, Jarchum S, Freue J, Miroli A, Guerrero O, López Ares L, Campestri R, Bove V, Salinas GN, Cabrejo M, Milone JH, Zabaljauregui S, Gotta D, Dupont JC, Stemmelin G. Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology. Medicina (B Aires) 2021; 81:536-545. [PMID: 34453794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Open
Abstract
Individuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall survival (OS) after COVID-19 infection in patients with a hematological disease in Argentina. A completely anonymous survey from the Argentine Society of Hematology was delivered to all the hematologists in Argentina; it started in April 2020. A cut-off to analyze the data was performed in December 2020 and, finally, 419 patients were reported and suitable for the analysis (average age: 58 years, 90% with malignant diseases). After the COVID-19 diagnosis, the 30-day OS for the whole population was 80.2%. From the entire group (419), 101 (24.1%) individuals required intensive care unit admission, where the 30-day OS was 46.6%. Among allogeneic stem cell transplant recipients, the 30-day OS was 70.3%. Factors associated with a low OS were two or more comorbidities, an active hematological disease and history of chemotherapy. In individuals with the three factors, the 30-day OS was 49.6% while the 30-day OS in those without those factors was 100%. Patients with hematological diseases have a higher mortality than the general population. This group represents a challenge and requires careful decision-making of the treatment in order not to compromise the chances of cure.
Collapse
Affiliation(s)
- Ana L Basquiera
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina. E-mail:
| | - Mercedes J García
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina
- Hospital Raúl Ferreyra, Córdoba, Argentina
| | | | | | | | - Rubén Burgos
- Conciencia-Instituto Oncohematológico de la Patagonia, Argentina
| | - Gastón Caeiro
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina
- Hospital Raúl Ferreyra, Córdoba, Argentina
| | | | - Pablo Raña
- Conciencia-Instituto Oncohematológico de la Patagonia, Argentina
| | | | | | | | | | | | | | | | - Analia Carvani
- Hospital Diego Paroissien, Isidro Casanova, Buenos Aires, Argentina
| | - Laura Mandrile
- Hospital Diego Paroissien, Isidro Casanova, Buenos Aires, Argentina
| | | | | | | | | | | | | | - Soledad Cruset
- Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | - María J Freitas
- Hospital Nacional Posadas, El Palomar, Buenos Aires, Argentina
| | | | | | - Irene Rey
- Hospital Ramos Mejía, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | - Victor Bove
- Instituto Oncohematológico Privado, Río Cuarto, Córdoba, Argentina
| | | | - María Cabrejo
- Sanatorio Municipal Julio Méndez, Buenos Aires, Argentina
| | | | | | - Daniel Gotta
- Hospital Urquiza, Concepción del Uruguay, Entre Ríos, Argentina
| | | | | |
Collapse
|
2
|
Dellavedova T, Boetto M, Olmedo J, Sarria JP, Nóbile R, Ponzano R, Quinteros L, Malizia Reynoso E, Minuzzi F. Enzalutamide as monotherapy for advanced prostate cancer: why not? ARCH ESP UROL 2016; 69:393-397. [PMID: 27617558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
OBJECTIVES Prostate cancer (PCa) is an androgen-dependent disease. In some cases, the tumor progresses despite castration levels of serum testosterone, turning into the lethal phenotype of castration-resistant prostate cancer (CRPC), still driven by androgens and requiring the androgen receptor as a driver and responsible for progression. Enzalutamide, an androgen receptor inhibitor, is indicated for the treatment of metastatic CRPC, asymptomatic or mildly symptomatic, after failure of androgen deprivation. In both clinical trials that led to its approval, Enzalutamide was administered with an LHRH analog, setting the "standard of care" for its use. In this article we evaluate the available evidence and theory on the use of Enzalutamide as monotherapy. METHODS Androgen deprivation well-known adverse events, together with the fact that its clinical benefit is moderate and the evidence strength is weak, and the direct negative impact on the common chronic conditions affecting this age-group led to investigation of Enzalutamide without LHRH analogs. RESULTS There are clinical trials on Enzalutamide monotherapy for hormone-sensitive prostate cancer with favourable outcomes, and there are also two ongoing studies in different advanced PCa scenarios, the PROSPER and EMBARK trials. It would be up to now a safe alternative, with less toxicity and lower costs. CONCLUSION It is mandatory to validate these early results on the use on Enzalutamide monotherapy for advanced prostate cancer, hormone-sensitive or castration resistant, metastatic or not, but in the meantime, we wonder, why not?
Collapse
Affiliation(s)
- T Dellavedova
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - M Boetto
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - J Olmedo
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - J P Sarria
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - R Nóbile
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - R Ponzano
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - L Quinteros
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - E Malizia Reynoso
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| | - F Minuzzi
- Fundación Urológica Córdoba para la Docencia e Investigación Médica (FUCDIM), Córdoba, Argentina
| |
Collapse
|
3
|
Zamora MJ, Alvarez M, Olmedo J, Blanco MC, Pozio E. Trichinella pseudospiralis in the Iberian peninsula. Vet Parasitol 2015; 210:255-9. [PMID: 25913596 DOI: 10.1016/j.vetpar.2015.04.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Revised: 03/31/2015] [Accepted: 04/02/2015] [Indexed: 11/16/2022]
Abstract
Nematode worms of the genus Trichinella are zoonotic parasites circulating in most continents, including Europe. In Spain, Trichinella spiralis and Trichinella britovi are highly prevalent in wildlife but seldom in domestic pigs. In Portugal, only T. britovi was documented in wild carnivores. In the period 2006-2013 in Spain, 384 (0.0001%) pigs and 1399 (0.20%) wild boars (Sus scrofa) were positive for Trichinella spp. larvae, which were identified as T. spiralis or T. britovi. In 2014, Trichinella pseudospiralis larvae were isolated from a wild boar hunted in the Gerona province, Cataluña region, North-East of Spain, near the border to France. This is the first report of T. pseudospiralis in the Iberian peninsula, which suggests a broad distribution area of this zoonotic nematode in Europe. Since larvae of this Trichinella species do not encapsulate in the host muscles, they can be detected only by artificial digestion of muscle samples. T. pseudospiralis is the only Trichinella species infecting both mammals and birds. Birds can spread this pathogen over great distances including islands triggering new foci of infections in areas previously considered at low risk for this pathogen.
Collapse
Affiliation(s)
- M J Zamora
- Servicio de Microbiología Alimentaria, Centro Nacional de Alimentación, Agencia Española de Consumo, Seguridad Alimentaria y Nutrición, Ctra. Pozuelo a Majadahonda, Km 5,100, 28220 Majadahonda, Madrid, Spain
| | - M Alvarez
- Servicio de Microbiología Alimentaria, Centro Nacional de Alimentación, Agencia Española de Consumo, Seguridad Alimentaria y Nutrición, Ctra. Pozuelo a Majadahonda, Km 5,100, 28220 Majadahonda, Madrid, Spain
| | - J Olmedo
- Servicio de Microbiología Alimentaria, Centro Nacional de Alimentación, Agencia Española de Consumo, Seguridad Alimentaria y Nutrición, Ctra. Pozuelo a Majadahonda, Km 5,100, 28220 Majadahonda, Madrid, Spain
| | - M C Blanco
- Servicio de Microbiología Alimentaria, Centro Nacional de Alimentación, Agencia Española de Consumo, Seguridad Alimentaria y Nutrición, Ctra. Pozuelo a Majadahonda, Km 5,100, 28220 Majadahonda, Madrid, Spain
| | - E Pozio
- Department of Infectious Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, Viale Regia Elena, 299, 00161 Rome, Italy.
| |
Collapse
|
6
|
Mañas MD, Domper A, Albillos A, Hernández A, Carpintero P, Lorente R, López B, De la Santa E, Olmedo J, Rodríguez E. Endoscopic follow-up of gastric ulcer in a population at intermediate risk for gastric cancer. Rev Esp Enferm Dig 2009; 101:317-324. [PMID: 19527077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
OBJECTIVES Primary: to assess the necessity of a second endoscopy with a pathology study to confirm the healing of all gastric ulcers previously diagnosed through endoscopy in a population at intermediate risk for gastric cancer. Secondary: to assess correlation between endoscopic findings and pathology diagnosis. PATIENTS AND METHODS a prospective analysis of patients diagnosed with gastric ulcer through endoscopy at Hospital General de Ciudad Real (Spain) over three years. We collected demographic, clinical, endoscopic, and pathological data for the first and subsequent endoscopies. We collected at least six biopsies obtained from ulcer margins, and assessed H. pylori infection. RESULTS Three hundred and two patients were included in this study. H. pylori infection was diagnosed in 173 (57%), and 113 (37%) patients had used NSAIDs. The positive and negative predictive value for malignancy of endoscopic diagnosis regarding ulcer fold, base, and margins were 34 and 97%, respectively. Only one patient was diagnosed with a tumor during the second endoscopy. At the end of follow-up, the etiology of the ulcer was considered as peptic in 276 patients; Crohn s disease-related in one, and neoplastic in 25 patients (21 adenocarcinomas, 4 lymphomas). CONCLUSIONS in an intermediate-risk population for gastric cancer a second endoscopy is not justified for gastric ulcer patients when endoscopy and biopsy results do not suggest malignancy.
Collapse
Affiliation(s)
- M D Mañas
- Service of Internal Medicine, Hospital General de Ciudad Real, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|